|
1
|
Heathcote EJ: Diagnosis and management of
cholestatic liver disease. Clin Gastroenterol Hepatol. 5:776–782.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Leary JG and Pratt DS: Cholestasis and
cholestatic syndromes. Curr Opin Gastroenterol. 23:232–236. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kimura A, Yuge K, Kosai KI, Kage M,
Fujisawa T, Inoue T, Yamashita Y, Nakashima E and Kato H: Neonatal
cholestasis in two siblings: a variant of Dubin-Johnson syndrome? J
Paediatr Child Health. 31:557–560. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trauner M, Fickert P, Halilbasic E and
Moustafa T: Lessons from the toxic bile concept for the
pathogenesis and treatment of cholestatic liver diseases. Wien Med
Wochenschr. 158:542–548. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Georgiev P, Jochum W, Heinrich S, Jang JH,
Nocito A, Dahm F and Clavien PA: Characterization of time-related
changes after experimental bile duct ligation. Br J Surg.
95:646–656. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fickert P, Trauner M, Fuchsbichler A,
Zollner G, Wagner M, Marschall HU, Zatloukal K and Denk H: Oncosis
represents the main type of cell death in mouse models of
cholestasis. J Hepatol. 42:378–385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Majno G and Joris I: Apoptosis, oncosis,
and necrosis. An overview of cell death. Am J Pathol. 146:3–15.
1995.PubMed/NCBI
|
|
8
|
Canbay A, Higuchi H, Bronk SF, Taniai M,
Sebo TJ and Gores GJ: Fas enhances fibrogenesis in the bile duct
ligated mouse: a link between apoptosis and fibrosis.
Gastroenterology. 123:1323–1330. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyoshi H, Rust C, Roberts PJ, Burgart LJ
and Gores GJ: Hepatocyte apoptosis after bile duct ligation in the
mouse involves Fas. Gastroenterology. 117:669–677. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patkowski W, Skalski M, Zieniewicz K,
Nyckowski P, Smoter P and Krawczyk M: Orthotopic liver
transplantation for cholestatic diseases. Hepatogastroenterology.
57:605–610. 2010.PubMed/NCBI
|
|
11
|
O'Leary JG, Lepe R and Davis GL:
Indications for liver transplantation. Gastroenterology.
134:1764–1776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esquivel CO: Liver transplantation: Where
we are and where we are heading. Transplant Proc. 42:610–612. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miyazawa K, Tsubouchi H, Naka D, Takahashi
K, Okigaki M, Arakaki N, Nakayama H, Hirono S, Sakiyama O,
Takahashi K, et al: Molecular cloning and sequence analysis of cDNA
for human hepatocyte growth factor. Biochem Biophys Res Commun.
163:967–973. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakamura T, Nishizawa T, Hagiya M, Seki T,
Shimonishi M, Sugimura A, Tashiro K and Shimizu S: Molecular
cloning and expression of human hepatocyte growth factor. Nature.
342:440–443. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura T, Sakai K, Nakamura T and
Matsumoto K: Hepatocyte growth factor twenty years on: much more
than a growth factor. J Gastroenterol Hepatol. 26(Suppl 1):
188–202. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ueki T, Kaneda Y, Tsutsui H, Nakanishi K,
Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto
E and Fujimoto J: Hepatocyte growth factor gene therapy of liver
cirrhosis in rats. Nat Med. 5:226–230. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kosai K, Matsumoto K, Funakoshi H and
Nakamura T: Hepatocyte growth factor prevents endotoxin-induced
lethal hepatic failure in mice. Hepatology. 30:151–159. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kosai K, Matsumoto K, Nagata S, Tsujimoto
Y and Nakamura T: Abrogation of Fas-induced fulminant hepatic
failure in mice by hepatocyte growth factor. Biochem Biophys Res
Commun. 244:683–690. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kosai KI, Finegold MJ, Thi-Huynh BT,
Tewson M, Ou CN, Bowles N, Woo SL, Schwall RH and Darlington GJ:
Retrovirus-mediated in vivo gene transfer in the replicating liver
using recombinant hepatocyte growth factor without liver injury or
partial hepatectomy. Hum Gene Ther. 9:1293–1301. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuge K, Takahashi T, Nagano S, Terazaki Y,
Murofushi Y, Ushikoshi H, Kawai T, Khai NC, Nakamura T, Fujiwara H
and Kosai K: Adenoviral gene transduction of hepatocyte growth
factor elicits inhibitory effects for hepatoma. Int J Oncol.
27:77–85. 2005.PubMed/NCBI
|
|
21
|
Ido A, Moriuchi A, Kim I, Numata M,
Nagata-Tsubouchi Y, Hasuike S, Uto H and Tsubouchi H:
Pharmacokinetic study of recombinant human hepatocyte growth factor
administered in a bolus intravenously or via portal vein. Hepatol
Res. 30:175–181. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ido A and Tsubouchi H: Translational
research to identify clinical applications of hepatocyte growth
factor. Hepatol Res. 39:739–747. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Mizuno S and Nakamura T:
Antinecrotic and antiapoptotic effects of hepatocyte growth factor
on cholestatic hepatitis in a mouse model of bile-obstructive
diseases. Am J Physiol Gastrointest Liver Physiol. 292:G639–G646.
2007. View Article : Google Scholar
|
|
24
|
Suzumura K, Hirano T, Son G, Iimuro Y,
Mizukami H, Ozawa K and Fujimoto J: Adeno-associated virus
vector-mediated production of hepatocyte growth factor attenuates
liver fibrosis in mice. Hepatol Int. 2:80–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia JL, Dai C, Michalopoulos GK and Liu Y:
Hepatocyte growth factor attenuates liver fibrosis induced by bile
duct ligation. Am J Pathol. 168:1500–1512. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kiso S, Kawata S, Tamura S, Higashiyama S,
Ito N, Tsushima H, Taniguchi N and Matsuzawa Y: Role of
heparin-binding epidermal growth factor-like growth factor as a
hepatotrophic factor in rat liver regeneration after partial
hepatectomy. Hepatology. 22:1584–1590. 1995.PubMed/NCBI
|
|
27
|
Higashiyama S, Abraham JA, Miller J,
Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted
by macrophage-like cells that is related to EGF. Science.
251:936–939. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kiso S, Kawata S, Tamura S, Umeki S, Ito
N, Tsushima H, Yamada A, Miyagawa J, Higashiyama S, Taniguchi N and
Matsuzawa Y: Effects of exogenous human heparin-binding epidermal
growth factor-like growth factor on DNA synthesis of hepatocytes in
normal mouse liver. Biochem Biophys Res Commun. 259:683–687. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Khai NC, Takahashi T, Ushikoshi H, Nagano
S, Yuge K, Esaki M, Kawai T, Goto K, Murofushi Y, Fujiwara T, et
al: In vivo hepatic HB-EGF gene transduction inhibits Fas-induced
liver injury and induces liver regeneration in mice: a comparative
study to HGF. J Hepatol. 44:1046–1054. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khai NC, Sakamoto K, Takamatsu H,
Matsufuji H and Kosai K: Recombinant soluble form of
heparin-binding epidermal growth factor-like growth factor protein
therapy drastically inhibits Fas-mediated fulminant hepatic
failure: implications in clinical application. Hepatol Res.
41:594–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Higashiyama S, Iwabuki H, Morimoto C,
Hieda M, Inoue H and Matsushita N: Membrane-anchored growth
factors, the epidermal growth factor family: beyond receptor
ligands. Cancer Sci. 99:214–220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang G, Besner GE and Brigstock DR:
Heparin-binding epidermal growth factor-like growth factor
suppresses experimental liver fibrosis in mice. Lab Invest.
92:703–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peifley KA, Alberts GF, Hsu DK, Feng SL
and Winkles JA: Heparin-binding epidermal growth factor-like growth
factor regulates fibroblast growth factor-2 expression in aortic
smooth muscle cells. Circ Res. 79:263–270. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang D, Zhang J, Jiang X, Li X, Wang Y,
Ma J and Jiang H: Heparin-binding epidermal growth factor-like
growth factor: a hepatic stellate cell proliferation inducer via
ErbB receptors. J Gastroenterol Hepatol. 29:623–632. 2014.
View Article : Google Scholar
|
|
35
|
Ushikoshi H, Takahashi T, Chen X, Khai NC,
Esaki M, Goto K, Takemura G, Maruyama R, Minatoguchi S, Fujiwara T,
et al: Local overexpression of HB-EGF exacerbates remodeling
following myocardial infarction by activating noncardiomyocytes.
Lab Invest. 85:862–873. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shiota G, Wang TC, Nakamura T and Schmidt
EV: Hepatocyte growth factor in transgenic mice: effects on
hepatocyte growth, liver regeneration and gene expression.
Hepatology. 19:962–972. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Takayama H, LaRochelle WJ, Sharp R, Otsuka
T, Kriebel P, Anver M, Aaronson SA and Merlino G: Diverse
tumorigenesis associated with aberrant development in mice
overexpressing hepatocyte growth factor/scatter factor. Proc Natl
Acad Sci USA. 94:701–706. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Takahashi T, Kawai T, Ushikoshi H, Nagano
S, Oshika H, Inoue M, Kunisada T, Takemura G, Fujiwara H and Kosai
K: Identification and isolation of embryonic stem cell-derived
target cells by adenoviral conditional targeting. Mol Ther.
14:673–683. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen XH, Minatoguchi S, Kosai K, Yuge K,
Takahashi T, Arai M, Wang N, Misao Y, Lu C, Onogi H, et al: In vivo
hepatocyte growth factor gene transfer reduces myocardial
ischemia-reperfusion injury through its multiple actions. J Card
Fail. 13:874–883. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yuge K, Takahashi T, Khai NC, Goto K,
Fujiwara T, Fujiwara H and Kosai K: Intramuscular injection of
adenoviral hepatocyte growth factor at a distal site ameliorates
dextran sodium sulfate-induced colitis in mice. Int J Mol Med.
33:1064–1074. 2014.PubMed/NCBI
|
|
41
|
Kountouras J, Billing BH and Scheuer PJ:
Prolonged bile duct obstruction: a new experimental model for
cirrhosis in the rat. Br J Exp Pathol. 65:305–311. 1984.PubMed/NCBI
|
|
42
|
Chen SH, Chen XH, Wang Y, Kosai K,
Finegold MJ, Rich SS and Woo SL: Combination gene therapy for liver
metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA.
92:2577–2581. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen SH, Kosai K, Xu B, Pham-Nguyen K,
Contant C, Finegold MJ and Woo SL: Combination suicide and cytokine
gene therapy for hepatic metastases of colon carcinoma: sustained
antitumor immunity prolongs animal survival. Cancer Res.
56:3758–3762. 1996.PubMed/NCBI
|
|
44
|
Terazaki Y, Yano S, Yuge K, Nagano S,
Fukunaga M, Guo ZS, Komiya S, Shirouzu K and Kosai K: An optimal
therapeutic expression level is crucial for suicide gene therapy
for hepatic metastatic cancer in mice. Hepatology. 37:155–163.
2003. View Article : Google Scholar
|
|
45
|
Caruso M, Pham-Nguyen K, Kwong YL, Xu B,
Kosai KI, Finegold M, Woo SL and Chen SH: Adenovirus-mediated
interleukin-12 gene therapy for metastatic colon carcinoma. Proc
Natl Acad Sci USA. 93:11302–11306. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Peeters MJ, Patijn GA, Lieber A, Meuse L
and Kay MA: Adenovirus-mediated hepatic gene transfer in mice:
Comparison of intravascular and biliary administration. Hum Gene
Ther. 7:1693–1699. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Veidal SS, Karsdal MA, Nawrocki A, Larsen
MR, Dai Y, Zheng Q, Hägglund P, Vainer B, Skjøt-Arkil H and Leeming
DJ: Assessment of proteolytic degradation of the basement membrane:
a fragment of type IV collagen as a biochemical marker for liver
fibrosis. Fibrogenesis Tissue Repair. 4:222011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hamaoka M, Chinen I, Murata T, Takashima
S, Iwamoto R and Mekada E: Anti-human HB-EGF monoclonal antibodies
inhibiting ectodomain shedding of HB-EGF and diphtheria toxin
binding. J Biochem. 148:55–69. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tsukada S, Parsons CJ and Rippe RA:
Mechanisms of liver fibrosis. Clin Chim Acta. 364:33–60. 2006.
View Article : Google Scholar
|
|
50
|
Uehara Y, Minowa O, Mori C, Shiota K, Kuno
J, Noda T and Kitamura N: Placental defect and embryonic lethality
in mice lacking hepatocyte growth factor/scatter factor. Nature.
373:702–705. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schmidt C, Bladt F, Goedecke S, Brinkmann
V, Zschiesche W, Sharpe M, Gherardi E and Birchmeier C: Scatter
factor/hepatocyte growth factor is essential for liver development.
Nature. 373:699–702. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Iwamoto R, Yamazaki S, Asakura M,
Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K,
Raab G, et al: Heparin-binding EGF-like growth factor and ErbB
signaling is essential for heart function. Proc Natl Acad Sci USA.
100:3221–3226. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kiso S, Kawata S, Tamura S, Higashiyama S,
Ito N, Tsushima H, Taniguchi N and Matsuzawa Y: Role of
heparin-binding epidermal growth factor-like growth factor as a
hepatotrophic factor in rat liver regeneration after partial
hepatectomy. Hepatology. 22:1584–1590. 1995.PubMed/NCBI
|
|
54
|
Esaki M, Takemura G, Kosai K, Takahashi T,
Miyata S, Li L, Goto K, Maruyama R, Okada H, Kanamori H, et al:
Treatment with an adenoviral vector encoding hepatocyte growth
factor mitigates established cardiac dysfunction in
doxorubicin-induced cardiomyopathy. Am J Physiol Heart Circ
Physiol. 294:H1048–H1057. 2008. View Article : Google Scholar
|
|
55
|
Li Y, Takemura G, Kosai K, Yuge K, Nagano
S, Esaki M, Goto K, Takahashi T, Hayakawa K, Koda M, et al:
Postinfarction treatment with an adenoviral vector expressing
hepatocyte growth factor relieves chronic left ventricular
remodeling and dysfunction in mice. Circulation. 107:2499–2506.
2003. View Article : Google Scholar : PubMed/NCBI
|
